Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the EGFR T790M mutation in non-small-cell lung cancer.

Expert opinion on therapeutic targets - 1 Feb 2017

Normanno Nicola, Maiello Monica Rosaria, Chicchinelli Nicoletta, Iannaccone Alessia, Esposito Claudia, De Cecio Rossella, D'alessio Amelia, De Luca Antonella

Abstract excerpt

INTRODUCTION: The presence of activating mutations of the epidermal growth factor receptor (EGFR) is predictive of response to first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with advanced non-small-cell lung cancer (NSCLC). However, patients that initially respond to these drugs inexorably become resistant. The T790M mutation in the exon 20 of the EGFR is the main mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to DNA, Neoplasm

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28002980
DOI: 10.1080/14728222.2017.1272582

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the EGFR T790M mutation in non-small-cell lung cancer.PMID 28002980Read ↗

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.Semantic proximity Read ↗

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.Semantic proximity Read ↗

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancerSemantic proximity Read ↗

[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.Semantic proximity Read ↗

Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.Semantic proximity Read ↗

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.Semantic proximity Read ↗

Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.Semantic proximity Read ↗

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.Semantic proximity Read ↗

Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.Semantic proximity Read ↗

Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.